T1	p 304 356	patients with chronic immune thrombocytopenia during
T2	p 359 366	6-month
T3	p 449 608	in adults with previously treated immune thrombocytopenia of more than 6 months ' duration who had baseline platelet counts lower than 30,000 per ?L . Patients
T4	p 1503 1560	Between Nov 22 , 2006 , and July 31 , 2007 , 197 patients
T5	p 1658 1696	( 135 eltrombopag , 62 placebo ) . 106
T6	p 2965 3011	patients who have not responded to splenectomy
T7	i 6 17	Eltrombopag
T8	i 155 169	thrombopoietin
T9	i 274 300	eltrombopag versus placebo
T10	i 424 442	placebo-controlled
T11	i 667 737	local standard of care plus 50 mg eltrombopag or matching placebo once
T12	i 1377 1384	placebo
T13	i 1681 1690	placebo )
T14	i 1838 1845	placebo
T15	i 1954 1961	placebo
T16	i 2094 2105	eltrombopag
T17	i 2175 2182	placebo
T18	i 2309 2316	placebo
T19	i 2436 2443	placebo
T20	i 2511 2518	placebo
T21	i 2657 2664	placebo
T22	i 2731 2738	placebo
T23	i 2818 2858	eltrombopag . INTERPRETATION Eltrombopag
T24	o 44 67	immune thrombocytopenia
T25	o 326 349	immune thrombocytopenia
T26	o 490 506	thrombocytopenia
T27	o 557 572	platelet counts
T28	o 937 953	thrombocytopenia
T29	o 960 971	splenectomy
T30	o 1106 1123	platelet response
T31	o 1153 1161	response
T32	o 1190 1204	platelet count
T33	o 1866 1876	responding
T34	o 2240 2263	needed rescue treatment
T35	o 2380 2401	thromboembolic events
T36	o 2544 2591	in alanine aminotransferase concentration , and
T37	o 2684 2701	total bilirubin .
T38	o 2743 2766	serious bleeding events
T39	o 2890 2921	chronic immune thrombocytopenia